On Thursday, Roche Holdings AG (OTC:RHHBY) said that the Phase 2/3 SKYSCRAPER-06 study of tiragolumab plus Tecentriq (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as first-line treatment for locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival (PFS) at its primary analysis. The hazard ratio (HR) was 1.27, and overall survival (OS) at its first interim analysis, with an HR of 1.
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens the door to a more personalized and effective treatment as messenger RNA instructs the patient’s cells how to combat diseases like cancer. Moderna Inc (NASDAQ: MRNA) and Merck & Co (NYSE: MRK) joined forces to advance cancer treatment with an experimental mRNA vaccine, used in combination with Merck
On Monday, Merck & Co Inc (NYSE:MRK) announced the notice of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208) into an exclusive global license for Merck. As previously announced under the companies’ original co-development and co-commercialization agreement, each party was granted an option to convert the co-exclusive license into an exclusive global license for Merck. Also Read: FDA Declines To